No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BIOR Biora Therapeutics
- 0.6904
- +0.0304+4.61%
Trading Jul 22 12:56 ET
24.82MMarket Cap-107P/E (TTM)
0.7000High0.6671Low109.77KVolume0.6800Open0.6600Pre Close75.25KTurnover1.02%Turnover RatioLossP/E (Static)35.94MShares3.950052wk High-0.25P/B7.42MFloat Cap0.475052wk Low--Dividend TTM10.74MShs Float398.0000Historical High--Div YieldTTM4.99%Amplitude0.4750Historical Low0.6850Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | HC Wainwright & Co. Reiterates Buy on Biora Therapeutics, Maintains $15 Price Target
Biora Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/22/2024 2015.95% HC Wainwright & Co. $15 → $15 Reiterates Buy → Buy 05/16/2024 2015.95% HC Wainwright &
Biora Therapeutics Buy Rating Confirmed by Positive Phase 1 Trial Outcomes and NaviCap Technology Potential
Biora Therapeutics Advances Ulcerative Colitis Treatment With BT-600 Trial Success
Express News | Biora Therapeutics Announces Supplemental Data From Phase 1 Clinical Trial of BT-600 as Presented at Kol Event
Biora Therapeutics to Host Virtual KOL Event on NaviCap Targeted Oral Delivery Platform and Results From Phase 1 Clinical Trial of BT-600 on July 17, 2024
SAN DIEGO, July 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company reimagining therapeutic delivery, today announced further details on its virtual event to be held on Wednesday,
Comments
$Biora Therapeutics(BIOR.US$
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
Biora Therapeutics (Nasdaq: BIOR) presented supplemental data from the Phase 1 trial of BT-600, an orally administered drug-device combination for ulcerative colitis treatment, at a virtual KOL event. The trial results demonstrated that BT-600, using Biora's NaviCap™ platform, successfully delivered tofacitinib directly to the colon, achieving higher ti...
Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event
Biora Therapeutics (Nasdaq: BIOR) presented supplemental data from the Phase 1 trial of BT-600, an orally administered drug-device combination for ulcerative colitis treatment, at a virtual KOL event. The trial results demonstrated that BT-600, using Biora's NaviCap™ platform, successfully delivered tofacitinib directly to the colon, achieving higher ti...
$Biora Therapeutics (BIOR.US)$ anyone know why sudden rise?
$Biora Therapeutics(BIOR.US$
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
Biora Therapeutics is set to host a virtual KOL event on July 17, 2024, to discuss its NaviCap™ Targeted Oral Delivery Platform and present Phase 1 clinical trial results for BT-600. The event will feature experts Bruce Sands and Brian Feagan, who will discuss the current treatment landscape for ulcerative co...
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
Biora Therapeutics is set to host a virtual KOL event on July 17, 2024, to discuss its NaviCap™ Targeted Oral Delivery Platform and present Phase 1 clinical trial results for BT-600. The event will feature experts Bruce Sands and Brian Feagan, who will discuss the current treatment landscape for ulcerative co...
$Biora Therapeutics(BIOR.US$ Biora Therapeutics Inc: BT-600 Was Well Tolerated and Met All Trial Objectives
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg